GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
HomeDrugsMariTide
GIPR antagonist/GLP-1Investigational · Phase 3

MariTide

GIP receptor antagonist and GLP-1 receptor agonist. Monthly (or less frequent).

MariTide (investigational)·Amgen

Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

OverviewDosing & warningsClinical trials

What to know about MariTide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−16.2% (-16.2% at 52 wks · Phase 2 obesity · Highest dose, monthly (Phase 2))

Phase 2 obesity · Highest dose, monthly (Phase 2)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Monthly (or less frequent)

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Indications

Investigational uses

MariTide (investigational)

Obesity; type 2 diabetes (investigational)

Obesity (investigational)Type 2 diabetes (investigational)

An investigational peptide-antibody conjugate that antagonizes the GIP receptor while agonizing the GLP-1 receptor, designed for infrequent (monthly) dosing.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

MariTide is investigational. See its registered studies below. Search DailyMed.

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Evidence

Clinical trials

26 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular…
    NCT07037433PHASE3Recruiting12,800 enrolled
  • Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
    NCT07037459PHASE3Recruiting5,056 enrolled
  • Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
    NCT06858839PHASE3Active_not_recruiting
Related

Related GLP-1s to compare

Semaglutide
Ozempic, Wegovy, Wegovy HD, Rybelsus
Tirzepatide
Mounjaro, Zepbound
Liraglutide
Victoza, Saxenda
Orforglipron
Foundayo
Questions

Common questions about MariTide

How much weight can you lose on MariTide?
In its pivotal trial (Phase 2 obesity), MariTide at Highest dose, monthly (Phase 2) showed a mean body-weight change of -16.2% at 52 wks. This is a trial average; individual results vary. Source
Is MariTide available yet?
No. MariTide is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
All shortagesPrice comparisonCompare drugsProvidersEvidence hubMethodology
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier
3,853 enrolled
  • Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
    NCT07684235PHASE3Recruiting3,200 enrolled
  • Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are…
    NCT06858878PHASE3Active_not_recruiting1,105 enrolled
  • Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
    NCT07684144PHASE3Recruiting950 enrolled
  • Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart…
    NCT07575399PHASE3Recruiting300 enrolled
  • Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
    NCT06987695PHASE3Active_not_recruiting279 enrolled
  • Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP)…
    NCT07226765PHASE3Active_not_recruiting250 enrolled
  • Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
    NCT07225686PHASE3Active_not_recruiting250 enrolled
  • Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity,…
    NCT05669599PHASE2Completed592 enrolled
  • A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
    NCT06660173PHASE2Active_not_recruiting409 enrolled

    • Source: ClinicalTrials.gov API v2 · as of Oct 3, 2026

    All trials on ClinicalTrials.gov